Lucky Rooster? A Stellar Year Ahead For Chinese Pharma Investment
If the year of the Monkey is a jumpy ride filled with uncertainties, the coming year of the Rooster will be certain to bring more changes to the pharma sector and immuno-oncology, high-end devices and combining artificial intelligence with next-generation genomics are attracting large amount of hot cash inflow.
You may also be interested in...
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.